The Psychotropic guidelines have been updated in response to the following drug approvals by the Australian Therapeutic Goods Administration. Here are the key changes:
A 6-month formulation of paliperidone palmitate is approved for maintenance treatment of schizophrenia in adults who have been adequately treated with a 1-monthly or 3-monthly formulation. New guidance on its use for recovery and relapse prevention in psychoses is included.
Intranasal esketamine is approved for treatment-resistant major depression (in conjunction with a newly initiated antidepressant), but its use and prescription should only be considered by specialists. Advice on its role in treatment-resistant major depression has been updated.
updated timeframes for dose titration of antipsychotics used for agitation, aggression or psychosis of dementia
the addition of hyperbolic tapering as an option for stopping antidepressants in patients at high risk of discontinuation symptoms.
Our new Therapeutic Guidelines app experience features elevated designs, enhanced search,
and intuitive navigation to streamline clinical workflows. Discover the next era of Therapeutic Guidelines.
Don’t have a subscription? Subscribe now.
